Introduction Infectious diarrhoea causes millions of deaths annually in low-income countries. Prevention strategies minimising transmission of diarrhoeal pathogens could include adopting better food ...

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), caused by carbapenem-resistant ...

While a randomized controlled trial of vitamin D 3 supplementation in COVID-19 patients didn’t yield a significant reduction ...

Cannabis compounds may reduce symptoms for some disorders, but evidence quality is low ...

BioVersys receives US FDA nod to recruit US patients for BV100 HABP/VABP phase 3 trial to treat hospital-acquired or ventilator-associated bacterial pneumonia: Basel, Switzerland ...

There was some evidence that cannabinoids can reduce symptoms of cannabis use disorder, insomnia, tic or Tourette's syndrome, and autism spectrum disorder, but the quality of this evidence was ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

T Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related ...

New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 ...

Canada: Researchers have found in a new randomized clinical trial that a 4-week vancomycin pulse and taper regimen showed a ...

Researchers have found in a pragmatic emergency-care study that adjunctive low-level laser therapy did not demonstrate a reduction in postoperative pain in permanent teeth with ...

The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive data from a successful clinical program ...